Search Results

You are looking at 211 - 220 of 2,734 items for :

  • Refine by Access: All x
Clear All
Full access

CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic

Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau

to the cancer center. Pembrolizumab ED has been evaluated through pharmacokinetic studies and simulated model-based analyses, however clinical data are lacking. The aim of this study is to evaluate real-world outcomes and safety of ED vs standard

Full access

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

worse outcome than tumors with other KIT or PDGFRA mutant isoforms or with no detectable mutation. 31 – 34 Conversely, KIT exon 11 mutations have been found in mitotically inactive GISTs 1 cm or less in size, suggesting that oncogenic KIT activity

Full access

HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng

and associated outcomes (time to treatment discontinuation [TTD] and treatment adherence) in selpercatinib-treated US patients. Methods: This retrospective cohort study used de-identified data from two administrative real-world claims databases

Full access

Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess

study, which reported that the most common toxicities were myelosuppression and gastrointestinal adverse effects. 15 Table 4 Clinical Outcomes by Tumor Type Taking into consideration that patients had a median of 4 prior therapies, and

Full access

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Aida Bujosa, Consolación Moltó, Thomas J. Hwang, José Carlos Tapia, Kerstin N. Vokinger, Arnoud J. Templeton, Ignasi Gich, Agustí Barnadas, Eitan Amir, and Ariadna Tibau

Background The FDA defines clinical benefit as an improvement in either the duration or the quality of life (QoL). 1 FDA criteria allow cancer drugs to be approved based on surrogate measures that will reasonably predict definitive outcomes

Full access

HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens

Daniel Simmons, Yang Xiao, Corina Roca, Zhuoxin Jiang, and Marnie Boron

-preferred regimens and describe their outcomes. Methods: We conducted a retrospective observational cohort study using US electronic health records from Flatiron Health. Patients were diagnosed with ES-SCLC between October 1st 2018 and June 30th 2022 and were

Full access

HSR22-166: Patient Demographic and Socioeconomic Differences in Non-Small Cell and Small Cell Lung Cancers: Impact on Outcomes. A National Cancer Database Analysis.

Logan Roof, Wei Wei, and James P Stevenson

communities, distance to an academic center, income, insurer, and education level. The goal of this study was to determine whether the same disparities exist in non-small cell lung cancer (NSCLC), and how the patient demographics and outcomes compare to those

Full access

CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity

Maria Philip, Jomon Raphael Chalissery, Febin Antony, Rajkrishna B, and Mathew Varghese K

to determine the benefits and overall survival in these patients treated with definitive radiotherapy with or without concurrent chemotherapy. Methods: We conducted a retrospective analysis to evaluate the clinical outcomes in patients with

Full access

EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data

Stephanie Lakritz, Anna Schreiber, Elizabeth Molina, Elisabeth Meyer, Cathy J Bradley, and Jennifer R Diamond

therapy (ATAX) regimens shown to be more efficacious compared to non-anthracycline-containing, taxane-based regimens (TAX) in node-positive disease. However, data investigating outcomes and utilization of adjuvant chemotherapy in older women with node

Full access

Multigene Sets for Clinical Application in Glioma

John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape

proliferation and necrosis. 1 Although histologic classification allowed patients with a single disease to be enrolled into clinical trials, and treatment protocols for these patients to be standardized, 2 outcomes were variable and could not be attributed to